Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

as grindeks - metformina e sitagliptina - metformina e sitagliptina

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unione Europea - italiano - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - metformini hydrochloridum, sitagliptinum - compresse rivestite con film - metformini hydrochloridum 500 mg, sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, cellulosum microcristallinum, povidonum k 29-32, natrii laurilsulfas, natrii stearylis fumaras, Überzug: poly(alcohol vinylicus), e 171, macrogola, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 1.025 mg. - diabetes typ 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - metformini hydrochloridum, sitagliptinum - compresse rivestite con film - metformini hydrochloridum 850 mg, sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, cellulosum microcristallinum, povidonum k 29-32, natrii laurilsulfas, natrii stearylis fumaras, Überzug: lactosum monohydricum 13.7 mg, hypromellosum, e 171, triacetinum, e 172 (rubrum), pro compresso obducto corresp. natrium 1.74 mg. - diabetes typ 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - metformini hydrochloridum, sitagliptinum - compresse rivestite con film - metformini hydrochloridum 1000 mg, sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, cellulosum microcristallinum, povidonum k 29-32, natrii laurilsulfas, natrii stearylis fumaras, Überzug: poly(alcohol vinylicus), macrogola, talcum, e 171, e 172 (rubrum), e 172 (nigrum), pro compresso obducto corresp. natrium 2.05 mg. - diabetes typ 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

axapharm ag - metformini hydrochloridum - 500 mg, compresse rivestite con film - metformini hydrochloridum 500 mg, povidonum k 90, magnesii stearas, Überzug: hypromellosum, macrogolum 400, macrogolum 6000 pro compresso obducto. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

axapharm ag - metformini hydrochloridum - 850 mg, compresse rivestite con film - metformini hydrochloridum 850 mg, povidonum k 90, magnesii stearas, Überzug: hypromellosum, macrogolum 400, macrogolum 6000 pro compresso obducto. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

axapharm ag - metformini hydrochloridum - 1000 mg, compresse rivestite con film - metformini hydrochloridum 1000 mg, povidonum k 90, magnesii stearas, Überzug: hypromellosum, macrogolum 400, macrogolum 6000 pro compresso obducto. - farmaco antidiabetico orale - synthetika